02637.HK
Fujian Haixi Pharmaceuticals Co., Ltd.
HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
HKD 199.30
−2.02%Aug 30, 2026, 15:26 UTC
Haixi New Drug (02637.HK) reported interim results for the six months ended June 2026, with revenue of RMB 312 million, up 3.9% year-on-year, and net profit attributable to shareholders of RMB 81.05 million, down 24.8%.
Source:Aug 17, 2026, 13:49 UTC
Haixi New Drug's candidate drug molecule HX9428 was granted Fast Track designation by the U.S. FDA for the treatment of neovascular age-related macular degeneration.
Source:Aug 4, 2026, 09:16 UTC
Haixi New Drug (02637) announced that it has officially initiated a second Phase II clinical study of HX9428 for treating nAMD in China, with the registration information disclosed on the NMPA CDE platform.
Source:Aug 4, 2026, 09:16 UTC
Haixi New Drug (02637) announced that its self-developed drug candidate HX9428 for treating neovascular age-related macular degeneration (nAMD) received U.S. FDA approval of its Investigational New Drug application to initiate a Phase II clinical trial.
Source:Jul 14, 2026, 09:19 UTC
HaiXi New Drug's HXP089 clinical trial application for glioblastoma treatment was approved by the National Medical Products Administration.
Source:Jul 9, 2026, 13:52 UTC
Haixi New Drug (02637) announced the initiation of a Phase III clinical trial for its novel multi-target drug C019199 tablet in osteosarcoma.